Study Overviews

• Trial 1: This study tested ORENCIA intravenous (IV) on 638 adults with moderate to severe rheumatoid arthritis who had not responded well enough to MTX. The participants were given either ORENCIA IV + MTX or MTX alone. At 6 months, the patients' signs and symptoms were measured, and at 1 year, their physical function and joint damage were assessed.
• Trial 2: This study tested ORENCIA IV on 389 adults with moderate to severe rheumatoid arthritis who had not responded well enough to a TNF* blocker (e.g., Humira^® (adalimumab), Enbrel^® (etanercept), or Remicade^® (infliximab)). The participants were given either ORENCIA IV plus a non-biologic DMARD^† or a non-biologic DMARD alone. Their signs and symptoms and their physical function were measured at 6 months.
• Trial 3: This study compared ORENCIA self-injection and ORENCIA IV in 1,457 patients with moderate to severe rheumatoid arthritis who had not responded well enough to MTX. The participants were given ORENCIA self-injection + MTX or ORENCIA IV + MTX. At 6 months, patients' signs and symptoms and their physical function were measured.

Improvement in Daily Activities

*DMARD: disease-modifying antirheumatic drug.
^†TNF: tumor necrosis factor.

ORENCIA^® (abatacept) helped improve people's ability
to perform physical tasks, such as dressing, grooming,
and walking.

• Trial 1 results: At 1 year, of people who received ORENCIA IV + MTX, 64% had an improvement in their physical function, compared to 39% of patients who received MTX alone.
• Trial 2 results: At 6 months, of the patients who received ORENCIA IV and a non-biologic DMARD, 47% had improvement in physical function, compared to 23% of those who received a non-biologic DMARD alone.
• Trial 3 results: At 6 months, participants' improvement in signs and symptoms as well as the reported side effects were comparable for ORENCIA self-injection and ORENCIA IV.

Your results may vary.

ORENCIA Helped Reduce Rheumatoid Arthritis Pain

*DMARD: disease-modifying antirheumatic drug.
^†TNF: tumor necrosis factor.

• Trial 1 results: After 6 months, patients on ORENCIA IV + MTX averaged a 42% reduction in pain. Those on MTX alone averaged a 3% reduction.
• Trial 2 results: At 6 months, patients on ORENCIA IV plus a non-biologic DMARD averaged a 28% reduction in pain. Those on a non-biologic DMARD alone averaged a 6% reduction.
• Trial 3 results: At 6 months, participants' improvement in signs and symptoms as well as the reported side effects were comparable for ORENCIA self-injection and ORENCIA IV.

Your results may vary.